Tricida Interest Expense 2011-2026 | TCDA

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Tricida

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
17.6 M	18.4 M	5.74 M	3.14 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
18.4 M	3.14 M	11.2 M

Quarterly Interest Expense Tricida

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	1.98 M	1.98 M	1.97 M	-	3.99 M	3.93 M	5.61 M	-	6.27 M	3.76 M	2.02 M	-	1.41 M	1.39 M	1.39 M	-	937 K	910 K	319 K	-	2 K	2 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.27 M	2 K	2.23 M

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.25	-3.02 %	$ 134 M	Canada
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Organogenesis Holdings ORGO	20 K	$ 4.17	-1.07 %	$ 549 M	USA
Emergent BioSolutions EBS	87.9 M	$ 12.94	-3.14 %	$ 663 M	USA
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	$ 21.52	0.19 %	$ 2.05 B	France
Sundial Growers SNDL	81 K	$ 1.65	0.3 %	$ 3.37 M	Canada
Sonoma Pharmaceuticals SNOA	-10 K	$ 3.65	-3.44 %	$ 4.53 M	USA
Evolus EOLS	127 K	$ 5.61	-2.35 %	$ 348 M	USA
Harrow Health HROW	21.3 M	$ 47.21	-7.51 %	$ 1.54 B	USA
China Pharma Holdings CPHI	27.4 K	$ 1.29	-4.79 %	$ 22.5 M	China
Tilray TLRY	46.6 M	$ 9.15	0.26 %	$ 5.65 B	Canada
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
Bausch Health Companies BHC	-28 M	$ 7.47	-3.93 %	$ 2.73 B	Canada
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Cumberland Pharmaceuticals CPIX	606 K	$ 4.78	-1.04 %	$ 67.2 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Veru VERU	862 K	$ 2.35	1.73 %	$ 317 M	USA
Pacira BioSciences PCRX	-373 K	$ 23.67	-9.03 %	$ 1.09 B	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Perrigo Company plc PRGO	900 K	$ 14.99	1.94 %	$ 2.06 B	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
cbdMD YCBD	-29.5 K	$ 1.08	-0.46 %	$ 4.66 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Rockwell Medical RMTI	2.3 M	$ 0.94	-3.6 %	$ 21.9 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 4.27	-3.61 %	$ 129 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
Assertio Holdings ASRT	2.78 M	$ 9.12	-2.04 %	$ 648 M	USA
Solid Biosciences SLDB	652 K	$ 5.25	-1.22 %	$ 214 M	USA
SCYNEXIS SCYX	3.13 M	$ 0.67	0.42 %	$ 32.1 M	USA
TherapeuticsMD TXMD	300 K	$ 2.09	1.46 %	$ 21.8 M	USA
Viatris VTRS	592 M	$ 12.74	1.07 %	$ 15.4 B	USA
Zomedica Corp. ZOM	175 K	-	-0.21 %	$ 98 M	USA